DO-BO

How to decode Market Access in Canada: Are there essential tips for success, Tara Cowling and Jody Filkowski?

In the newest episode of MAP – the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada’s market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.

Whether you’re dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by industry professionals working within the Canadian healthcare system. They also share insights about the emerging role of digital health in Canada, and the potential changes with the introduction of the Canadian Drug Agency.

Related

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe […]

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]